Showing 1765 results
-
Ad hoc release /Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
Ad hoc release /
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD)Key growth drivers continued strong sales momentum including Entresto… -
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority…
-
Press release /Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid term European champion committed to…
-
Ad hoc release /Im dritten Quartal 2020 lag der Nettoumsatz der fortzuführenden Geschäftsbereiche1 auf dem Niveau des Vorjahres (kWk2, +1% USD): Zu den Wachstumsträgern gehörten Entresto (USD 632 …
-
Press release /– A mean increase in CHOP-INTEND of 17.3 was observed at three months post gene therapy in SMA Type 1 U.S. pivotal trial – – All patients in the therapeutic dose cohort in the Phase 1 trial…
-
Ad hoc release /Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Press release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche[1] steigt aufgrund folgender Beiträge um 8% (kWk[2], +4% USD): Cosentyx erzielt einen Umsatz von USD 858 Millionen (+25% kWk), vor allem dank…
-
Press release /The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…